About Azanta
Azanta is a Healthcare company based in Copenhagen (Denmark) founded in 1994 by Claus Juan Moller San Pedro, and was acquired by Norgine in March 2020. Medicines for orphan oncology and womens health devices are developed. Azanta has raised $15.82 million across 2 funding rounds from investors including Norgine, European Equity Partners and Norgine Ventures. The company has 3 employees. Its chief executive, as recorded, is Claus Juan Moller San Pedro. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer. Its legal entity is Azanta A/S.
Company details
Azanta was founded in 1994 in Copenhagen, Denmark, focusing on the pharmaceutical and medical device sectors. Treatments for orphan oncology indications are developed, alongside devices for womens health monitoring. Lead candidates include Nimoral and Angusta. A range of specialty pharmaceutical products is marketed and distributed via third-party agreements. Operations center on intrauterine devices for contraception, such as the CE-approved Silverline Cu 380 and Flexi-T.
- Headquarters Copenhagen, Denmark
- Employees 3
- Founders Claus Juan Moller San Pedro
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website azanta.com
- Acquired by Norgine (Mar 2020)
- Legal Name Azanta A/S
Funding Insights of Azanta
Azanta has successfully raised a total of $15.82M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $6.98 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.82M
- Total Rounds 2
- Last Round Series B — $6.98M
- First Round $8.84M
(Oct 2014)
- Investors Count 2
All 2 funding rounds of Azanta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $6.98M | Series B | – | European Equity Partners | – |
| Oct 2014 | $8.84M | Series B | – | Norgine Ventures | – |
3 investors in total: 3 institutional.
Investors in Azanta
Azanta has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Norgine, European Equity Partners and Norgine Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in life sciences companies is facilitated by EEP. | eeplp.com | London, United Kingdom | ||
| norgineventures.com | ||||
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed. | 1906 | norgine.com | Amsterdam, Netherlands |
Investor details for Azanta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Azanta
2 people are tracked at Azanta (2 in leadership); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Claus Juan Moller San Pedro | Founder & ex-CEO | Leadership |
Wolfgang Amann | CEO | Leadership |
Complete people profiles for Azanta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Azanta
4 dated milestones of Azanta across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Azanta is founded.
- Funding First funding round of $8.8M.
- Funding Latest funding round, Series B, of $7.0M.
- Exit Acquired by Norgine.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Azanta
Azanta was founded in 1994 and raised its 1st funding round 20 years after it was founded.
Azanta is headquartered in Copenhagen, Denmark.
Claus Juan Moller San Pedro is the CEO of Azanta, as recorded in our data. They have also founded this company.
Azanta is a funded company, having raised a total of $15.82M across 2 funding rounds to date. The company's 1st funding round was a Series B of $8.84M, raised on Oct 2014.
Azanta has 3 employees.
Annual revenue of Azanta is $6.92K as on Dec 31, 2018.
Azanta was founded in 1994 in Copenhagen, Denmark, focusing on the pharmaceutical and medical device sectors. Treatments for orphan oncology indications are developed, alongside devices for womens health monitoring. Lead candidates include Nimoral and Angusta. A range of specialty pharmaceutical products is marketed and distributed via third-party agreements. Operations center on intrauterine devices for contraception, such as the CE-approved Silverline Cu 380 and Flexi-T.
Azanta has 3 investors. Key investors include Norgine, European Equity Partners, and Norgine Ventures.
Azanta operates through Azanta A/S.
Yes. Azanta was acquired by Norgine in March 2020.